My ALT and AST came back high — should I stop the cycle?

The decision matrix has three inputs: which compound class you are running (oral 17α-alkylated vs injectable), the ratio of AST to ALT and the CK reading (muscle vs liver source differential), and the absolute ALT value relative to upper reference limit. Each combination produces a different action. The raw “my ALT is 85” reading does not contain enough information to decide on its own.

Source differential — the AST/ALT/CK triangulation

ALT (alanine aminotransferase) is the more hepatocyte-specific enzyme. AST (aspartate aminotransferase) is expressed in hepatocytes but also in skeletal muscle, cardiac muscle, and erythrocytes. CK (creatine kinase) is muscle-specific. The pattern of these three discriminates muscle-origin elevation from hepatic-origin elevation:

• Muscle origin: AST elevated, ALT mildly elevated or normal, CK markedly elevated, AST/ALT ratio >1. Classic pattern after a heavy training session or rhabdo-lite. No liver pathology indicated.
• Hepatic origin (oral AAS): ALT elevated, AST elevated proportionally, CK normal or only mildly raised, AST/ALT ratio ≈ 1. Indicates hepatocellular leakage from drug-induced liver stress.
• Cholestatic injury (oral AAS, especially stanozolol): GGT and ALP elevated disproportionately to ALT, direct bilirubin rising. ALT may be only mildly elevated. The pattern that indicates bile-flow obstruction rather than hepatocyte injury — different mechanism, different response.
• Alcoholic hepatitis pattern (concurrent alcohol use): AST/ALT ratio >2, GGT markedly elevated. The muscle-vs-hepatic differential becomes ambiguous if both contributions are present.

Pre-test conditions that produce false-elevated ALT/AST

Skeletal-muscle release dominates the differential at most pre-test errors:

• Heavy training within 48–72 hours pre-draw can push ALT from 25 to 85 and AST from 25 to 110 with normal liver function. Deadlift or squat sessions specifically — high-mass concentric/eccentric work — produce the largest spikes.
• Rhabdomyolysis-borderline events (extreme training intensity, inadequate hydration, pre-workout stimulant use, novel exercise modalities) push ALT into the 150+ range purely from skeletal muscle.
• Recent alcohol consumption (within 48 hours).
• Acetaminophen/paracetamol within 48 hours (additive hepatic stress with any AAS background exposure).

Protocol: 72-hour training rest before any liver panel. If the panel was pulled after a heavy session and ALT is elevated, repull in a week with proper rest before making protocol decisions. Order CK simultaneously to enable the muscle-vs-liver differential calculation.

Context-dependent decision matrix — oral 17α-alkylated cycle

17α-alkylated orals (methandrostenolone, oxandrolone, stanozolol, oxymetholone, fluoxymesterone, methyltestosterone) produce expected dose-dependent ALT/AST elevation. The expected magnitude varies by compound — oxandrolone produces 1.5–2× elevations at standard dose; oxymetholone and methyltestosterone produce 2–4× elevations. The decision threshold is anchored to upper reference limit (ULN), not to absolute values:

Context-dependent decision matrix — injectable-only cycle

Injectable testosterone esters, nandrolone, boldenone, drostanolone, trenbolone, methenolone enanthate are not hepatotoxic at clinical doses. ALT/AST elevation on a pure injectable protocol indicates a different cause:

• Recent intense training (most common explanation; verify with CK).
• Alcohol exposure or acetaminophen use.
• Concurrent hepatotoxic supplement (some pre-workouts contain hepatotoxic ingredients; certain herbal supplements — green tea extract at high dose, kava, comfrey — produce idiosyncratic hepatic injury).
• Underlying viral hepatitis or other hepatic pathology unrelated to the cycle (request hepatitis B/C serology and abdominal ultrasound if persistent elevation).
• Trenbolone-specific: produces apparent creatinine elevation due to haem-pigment renal excretion, but this should not affect ALT/AST. Persistent elevation on tren-containing cycles warrants the differential workup above.

Discontinuation protocol — when stopping is the correct call

Acute stopping of a multi-compound cycle is rarely the right answer; controlled drop of the offending compound while maintaining the testosterone base is. The reasoning: testosterone base preserves normal protein synthesis and metabolic function during the recovery window, prevents acute crash hypogonadism, and does not contribute to ongoing hepatic stress. The oral is the variable to remove.

Recovery support:

• TUDCA 500 mg/day, split AM/PM. Bile-acid pool displacement, reduces hepatic cholate accumulation. Mechanism is solid in cholestatic disease; AAS-specific evidence is mechanistically plausible.
• NAC 1200 mg/day. Glutathione precursor; replenishes the cofactor depleted by alkylated-oral metabolism.
• Total alcohol avoidance during recovery and for 4 weeks beyond. Ethanol via CYP2E1 is synergistic with residual hepatic stress, not additive.
• No acetaminophen.

Recheck at 3 weeks. Expected: ALT down 30–50% from peak. If values continue rising or are stable past week 6 of cessation, the cause is unlikely to resolve with supplementation alone — clinical hepatology referral is the indicated next step. Persistent elevation past 12 weeks of cessation requires workup for chronic liver disease (autoimmune hepatitis, viral hepatitis, NAFLD) that the AAS exposure may have unmasked rather than caused.